세계의 바이오마커 시장 보고서 : 동향, 예측, 경쟁 분석(-2030년)

Biomarker Trends and Forecast

The future of the global biomarker market looks promising with opportunities in the diagnostic, drug discovery & development, personalized medicine, and disease risk assessment markets. The global biomarker market is expected to reach an estimated $110.5 billion by 2030 with a CAGR of 8.8% from 2024 to 2030. The major drivers for this market are a growing preference for personalized medicine and rising government support for biomarker research and development.

• Lucintel forecasts that, within the product category, consumables will remain the largest segment over the forecast period.
• Within the application category, diagnostics will remain the largest segment over the forecast period.
• In terms of regions, North America will remain the largest region due to the growing population with chronic diseases and the presence of key players in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Biomarker Market

The biomarker market is evolving rapidly, driven by technological innovations, growing demand for personalized medicine, and increasing healthcare complexities. Emerging trends are reshaping how biomarkers are discovered, validated, and applied, with significant implications for clinical practice and drug development. Understanding these trends provides insight into the future direction of the market and the potential impact on patient care and treatment outcomes.

• Advancement in Genomic and Proteomic Technologies: The integration of next-generation sequencing (NGS) and advanced proteomics technologies is revolutionizing biomarker discovery. These advancements enable more comprehensive and precise identification of biomarkers related to genetic and protein expressions. This trend enhances the accuracy of disease diagnosis and the development of targeted therapies, paving the way for personalized medicine. The ability to analyze complex biological data at a granular level improves the early detection of diseases and the monitoring of treatment efficacy.
• Growth of Liquid Biopsies: Liquid biopsies, which analyze biomarkers from blood samples, are becoming increasingly popular due to their non-invasive nature and ability to provide real-time insights into disease progression. This trend is particularly significant in oncology, where liquid biopsies facilitate early cancer detection and monitoring of treatment responses. The development of more sensitive and specific assays is expanding the utility of liquid biopsies beyond cancer, potentially impacting various disease areas and improving patient management.
• Integration of Artificial Intelligence and Machine Learning: Artificial intelligence (AI) and machine learning (ML) are transforming biomarker research by enhancing data analysis, pattern recognition, and predictive modeling. These technologies streamline the biomarker discovery process, improve diagnostic accuracy, and enable more effective drug development. AI-driven algorithms can process vast amounts of biological data to identify novel biomarkers and predict patient responses to treatments, thereby accelerating the pace of innovation and improving personalized healthcare solutions.
• Increased Focus on Personalized Medicine: Personalized medicine, which tailors treatments based on individual genetic and molecular profiles, is driving demand for biomarkers that can predict treatment responses and outcomes. This trend is leading to the development of targeted therapies and companion diagnostics, which are improving treatment efficacy and reducing adverse effects. Personalized medicine is also fostering the growth of biomarker-based clinical trials, enabling more precise patient stratification and enhancing the overall effectiveness of therapeutic interventions.
• Emergence of Multi-Omics Approaches: Multi-omics approaches, which integrate genomics, proteomics, metabolomics, and other 'omics' technologies, are providing a more comprehensive understanding of biological systems. This trend allows for the identification of biomarkers with greater specificity and sensitivity, facilitating a holistic view of disease mechanisms and therapeutic targets. By combining data from multiple 'omics' layers, researchers can uncover complex interactions and pathways, leading to more accurate disease characterization and novel biomarker discoveries.

These emerging trends are collectively advancing the biomarker market by enhancing the precision of diagnostics, expanding the scope of biomarker applications, and fostering innovation in personalized medicine. The integration of advanced technologies and approaches is leading to more effective and tailored healthcare solutions, ultimately improving patient outcomes and driving the growth of the biomarker industry.

Recent Developments in the Biomarker Market

Recent key developments in the biomarker market reflect a landscape marked by technological progress, increased investment, and a growing emphasis on personalized healthcare. These developments are shaping the future of biomarker applications, from drug discovery to clinical diagnostics, and are influencing the strategies of major players in the industry. Understanding these developments offers insight into the market's trajectory and its impact on healthcare practices worldwide.

• Advancements in Genomic Sequencing: The continued advancement in genomic sequencing technologies, including next-generation sequencing (NGS), has significantly improved the ability to identify and validate biomarkers. Enhanced sequencing capabilities allow for more detailed genomic analyses, leading to a better understanding of genetic variations and their role in diseases. This development is driving the discovery of novel biomarkers, facilitating precision medicine approaches, and improving disease diagnosis and treatment strategies.
• Expansion of Liquid Biopsy Applications: Liquid biopsies have expanded beyond oncology to other areas such as cardiovascular diseases and prenatal screening. The development of more sensitive and specific liquid biopsy assays enables non-invasive monitoring of disease progression and treatment responses. This expansion is enhancing the clinical utility of liquid biopsies, providing patients with more accessible and less invasive diagnostic options, and supporting the growth of personalized treatment approaches.
• Integration of Artificial Intelligence in Biomarker Discovery: Artificial intelligence (AI) is increasingly being integrated into biomarker discovery and development processes. AI algorithms analyze large datasets to identify potential biomarkers and predict their relevance in various diseases. This integration accelerates the biomarker discovery process, enhances the accuracy of biomarker validation, and supports the development of new diagnostic and therapeutic tools, driving innovation in the biomarker market.
• Development of Companion Diagnostics: The rise of companion diagnostics, which are tests used to determine the suitability of a particular therapeutic approach for individual patients, is a significant development in the biomarker market. These diagnostics are increasingly used to tailor treatments to specific biomarker profiles, improving treatment efficacy and minimizing adverse effects. The growth of companion diagnostics is fostering a more personalized approach to medicine and supporting the development of targeted therapies.
• Increased Investment and Collaboration in Biomarker Research: There has been a notable increase in investment and collaboration in biomarker research from both the public and private sectors. This trend is driven by the recognition of biomarkers' potential in advancing personalized medicine and improving healthcare outcomes. Increased funding supports research initiatives, facilitates the development of innovative biomarker technologies, and promotes partnerships between biotech firms, academic institutions, and pharmaceutical companies, driving progress in the biomarker market.

These recent developments are collectively driving the biomarker market toward more advanced, precise, and personalized healthcare solutions. Technological advancements, expanded applications, and increased investment are reshaping the market, enhancing the capabilities of biomarkers in diagnostics and treatment, and fostering continued innovation in the field.

Strategic Growth Opportunities for Biomarker Market

The biomarker market is experiencing a transformative phase driven by advancements in technology and an increasing focus on personalized medicine. Biomarkers are pivotal in diagnosing diseases, predicting treatment responses, and tailoring therapies to individual patient profiles. This has created fertile ground for strategic growth across various applications. As the market evolves, key growth opportunities are emerging that leverage innovations in genomics, proteomics, and diagnostics. Understanding these opportunities is essential for stakeholders aiming to capitalize on the burgeoning potential of biomarkers in improving patient outcomes and driving market expansion.

• Oncology Diagnostics: With cancer being a leading cause of death globally, there is a heightened demand for precise diagnostic tools. Advances in genomics and proteomics are facilitating the development of biomarkers that can identify cancer at an early stage, predict disease progression, and personalize treatment. Innovative liquid biopsy technologies are particularly promising, offering non-invasive alternatives to traditional tissue biopsies. This advancement not only enhances early detection but also improves patient management by tailoring therapies to individual genetic profiles, ultimately driving significant growth in the oncology diagnostics sector.
• Cardiovascular Disease Monitoring: Cardiovascular diseases (CVD) remain a major global health challenge. Biomarkers play a crucial role in monitoring CVD by assessing risk factors and predicting outcomes. Advances in proteomics and metabolomics are leading to the discovery of novel biomarkers that provide insights into heart disease mechanisms, risk stratification, and treatment response. For instance, biomarkers like high-sensitivity troponin and natriuretic peptides are being increasingly used to enhance diagnostic accuracy and guide therapeutic interventions, creating substantial growth potential in cardiovascular disease monitoring and management.
• Neurological Disorder Management: Neurological disorders, such as Alzheimer's and Parkinson's disease, present complex diagnostic and management challenges. Biomarkers are crucial in diagnosing these conditions early and monitoring disease progression. Recent advancements in neuroimaging and cerebrospinal fluid analysis have led to the identification of biomarkers that can differentiate between types of neurological disorders and predict patient outcomes. By enabling early intervention and personalized treatment approaches, these advancements offer significant growth opportunities in the neurological biomarker market, improving patient care and potentially altering disease trajectories.
• Infectious Disease Diagnosis: The rise of emerging and re-emerging infectious diseases underscores the need for rapid and accurate diagnostic tools. Biomarkers can facilitate the swift identification of pathogens, determine disease severity, and monitor response to treatment. Recent developments in molecular diagnostics and high-throughput screening technologies are enhancing the ability to detect and quantify biomarkers associated with infectious agents. This progress is critical for managing outbreaks and improving public health responses, presenting a significant growth opportunity in the infectious disease diagnosis sector.
• Personalized Medicine: The shift towards personalized medicine is transforming how diseases are treated by tailoring therapies to individual genetic and molecular profiles. Biomarkers are central to this approach, enabling the identification of patients who are likely to benefit from specific treatments. Innovations in genomics and bioinformatics are accelerating the discovery of biomarkers that guide personalized therapy decisions. This trend is driving substantial growth in the personalized medicine market, as it enhances treatment efficacy and reduces adverse effects, making it a key area for strategic investment and development.

The biomarker market offers substantial growth opportunities driven by advancements in personalized medicine, genomic technologies, early disease detection, companion diagnostics, and increased investment in research. By focusing on these strategic areas, stakeholders can leverage emerging trends to develop innovative solutions and address the growing demand for precise, effective, and personalized healthcare. Navigating these opportunities effectively will enable companies to enhance their market position, contribute to the advancement of medical science, and ultimately improve patient outcomes across a range of therapeutic areas.

Biomarker Market Driver and Challenges

The biomarker market is influenced by a complex interplay of technological, economic, and regulatory factors. Key drivers are advancing technology, growing demand for personalized medicine, increasing prevalence of chronic diseases, supportive government initiatives, and rising healthcare expenditures. However, the market also faces challenges such as high costs of development, stringent regulatory requirements, data privacy concerns, and limited reimbursement. Understanding these drivers and challenges is crucial for stakeholders to navigate the market landscape effectively and capitalize on emerging opportunities.

The factors responsible for driving the biomarker market include:

1. Advancing Technology: Technological advancements in genomics, proteomics, and molecular diagnostics are pivotal for biomarker discovery and application. Innovations such as next-generation sequencing (NGS) and high-throughput screening have significantly accelerated biomarker identification and validation processes. These technologies enhance diagnostic accuracy, enable personalized treatment approaches, and drive market growth by facilitating the development of novel biomarkers for various applications. Continuous technological evolution ensures the introduction of more sophisticated and reliable biomarker-based solutions, contributing to the overall expansion of the biomarker market.

2. Growing Demand for Personalized Medicine: The increasing emphasis on personalized medicine is a major driver of the biomarker market. Personalized medicine relies on biomarkers to tailor treatments to individual patients based on their genetic and molecular profiles. This approach improves treatment outcomes and minimizes adverse effects, leading to higher demand for biomarker-based diagnostics and therapeutics. As healthcare shifts towards more individualized care, the need for biomarkers that guide personalized treatment decisions is expected to grow, driving substantial market growth and innovation.

3. Increasing Prevalence of Chronic Diseases: The rising incidence of chronic diseases such as cancer, cardiovascular disorders, and diabetes is fueling demand for biomarkers. Biomarkers are essential for early diagnosis, disease monitoring, and personalized treatment of these conditions. As the global burden of chronic diseases continues to grow, there is an increasing need for effective biomarker-based diagnostic and therapeutic solutions. This trend drives market growth by expanding the application scope of biomarkers and encouraging investment in research and development.

4. Supportive Government Initiatives: Government initiatives and funding programs play a crucial role in advancing biomarker research and development. Many governments are investing in initiatives aimed at promoting precision medicine, supporting biomarker discovery, and facilitating regulatory approvals. Such support includes grants, subsidies, and collaborations with research institutions. These initiatives accelerate innovation, reduce financial barriers, and foster a favorable environment for biomarker market growth, making it a significant driver in the industry.

5. Rising Healthcare Expenditures: Increased healthcare spending globally is driving demand for advanced diagnostic and therapeutic solutions, including biomarkers. Higher healthcare budgets allow for greater investment in research, development, and implementation of cutting-edge biomarker technologies. This trend enhances access to innovative biomarker-based diagnostics and treatments, supporting market growth. As healthcare systems prioritize advanced and personalized approaches, rising expenditures contribute to the expansion and advancement of the biomarker market.

Challenges in the biomarker market are:

1. High Costs of Development: The high cost of developing and validating biomarkers poses a significant challenge to market growth. The process involves extensive research, clinical trials, and regulatory compliance, which can be financially burdensome. These costs can limit the ability of smaller companies to enter the market and slow down the development of new biomarkers. Addressing these financial challenges is crucial for ensuring a steady flow of innovation and making advanced biomarker solutions more accessible and affordable.

2. Stringent Regulatory Requirements: The biomarker market faces challenges related to complex and stringent regulatory requirements. Regulatory agencies require rigorous validation and evidence of clinical utility before approving biomarker-based diagnostics and therapeutics. Navigating these regulations can be time-consuming and costly, potentially delaying product development and market entry. Streamlining regulatory processes and providing clearer guidelines could help mitigate these challenges and facilitate smoother market access for new biomarker innovations.

3. Data Privacy Concerns: The collection and analysis of sensitive patient data for biomarker research raise significant data privacy concerns. Ensuring compliance with data protection regulations, such as the GDPR and HIPAA, is essential for maintaining patient trust and avoiding legal issues. However, stringent privacy requirements can complicate data sharing and collaboration, potentially hindering research progress. Balancing data privacy with the need for comprehensive research is a key challenge that impacts the efficiency and effectiveness of biomarker development.

The biomarker market is driven by technological advancements, the growing demand for personalized medicine, and the rising prevalence of chronic diseases, supported by favorable government initiatives and increased healthcare expenditures. However, challenges such as high development costs, stringent regulatory requirements, and data privacy concerns can impact market dynamics. Overall, while these drivers contribute to significant growth opportunities and innovation, the challenges necessitate strategic approaches to ensure continued progress and market expansion. Addressing these issues effectively will be crucial for realizing the full potential of the biomarker market and enhancing patient care.

List of Biomarker Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies biomarker companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biomarker companies profiled in this report include-

• Abbott Laboratories
• QIAGEN
• PerkinElmer
• Merck
• Bio-Rad Laboratories
• Enzo Biochem
• Charles River Laboratories
• Siemens
• Epistem
• Eurofins Scientific

Biomarker by Segment

The study includes a forecast for the global biomarker by product, type, disease indication, application, and region.

Biomarker Market by Product [Analysis by Value from 2018 to 2030]:

• Consumables
• Services
• Software

Biomarker Market by Type [Analysis by Value from 2018 to 2030]:

• Safety Biomarkers
• Efficacy Biomarkers
• Predictive Biomarkers
• Surrogate Biomarkers
• Pharmacodynamics Biomarkers
• Prognostic Biomarkers
• Validation Biomarkers

Biomarker Market by Disease Indication [Analysis by Value from 2018 to 2030]:

• Cancer
• Infectious Diseases
• Immune Disorders
• Neurological Disorders
• Cardiovascular Disorders
• Others

Biomarker Market by Application [Analysis by Value from 2018 to 2030]:

• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment
• Others

Biomarker Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Biomarker Market

The biomarker market has experienced significant growth and transformation due to advances in technology, increasing healthcare needs, and a rising focus on personalized medicine. Biomarkers biological indicators used for diagnosis, prognosis, and treatment monitoring are now pivotal in drug development, disease management, and clinical diagnostics. This market's expansion is influenced by innovations in molecular biology, genomics, and proteomics, alongside varying regulatory environments and healthcare priorities in key global regions. Understanding recent developments in major markets like the United States, China, Germany, India, and Japan offers insight into how regional dynamics shape the global biomarker landscape.

• United States: The U.S. biomarker market continues to lead in innovation, driven by strong investment in research and development and a robust healthcare infrastructure. Key developments include advancements in genomic biomarkers and liquid biopsies, which are enhancing early cancer detection and personalized treatments. Regulatory bodies like the FDA are increasingly supportive of novel biomarker applications, facilitating faster approval processes. Additionally, the rise of artificial intelligence and machine learning is improving biomarker discovery and validation, making the U.S. a hub for cutting-edge biomarker technologies.
• China: China's biomarker market is expanding rapidly due to government support and significant investments in biotechnology. The country is focusing on developing biomarkers for chronic diseases, including cancer and cardiovascular conditions, driven by its large patient population. Recent advancements include increased collaboration between Chinese biotech firms and international partners, which is accelerating biomarker research and development. Additionally, China's growing emphasis on precision medicine and the integration of artificial intelligence are transforming biomarker discovery and application, positioning the country as a key player in the global market.
• Germany: Germany is advancing in the biomarker sector through strong research institutions and a collaborative approach between academia and industry. The country is notable for its progress in biomarker-based diagnostics and personalized medicine. Recent developments include improvements in biomarkers for neurodegenerative diseases and the implementation of advanced genomics and proteomics technologies. Germany's regulatory environment supports innovation while ensuring rigorous standards, facilitating the development and commercialization of new biomarker-based products. The integration of biomarker technologies into routine clinical practice is also enhancing disease management and treatment outcomes.
• India: India's biomarker market is growing as a result of increasing healthcare investments and a rising focus on personalized medicine. Recent developments highlight advances in biomarkers for infectious diseases, cancer, and metabolic disorders. The Indian government's initiatives to enhance healthcare infrastructure and support biotech research are driving growth. Additionally, collaborations between Indian research institutions and global pharmaceutical companies are accelerating biomarker discovery and application. Despite challenges such as regulatory hurdles and infrastructure limitations, India is making significant strides in biomarker research, contributing to both local and global healthcare improvements.
• Japan: Japan's biomarker market is marked by innovation and strong technological advancements. Recent developments include significant progress in biomarkers for oncology, with a focus on early detection and targeted therapies. Japan research institutions are actively involved in developing novel biomarkers and integrating them into clinical practice. The country's regulatory framework supports the rapid approval of new biomarker-based diagnostics and treatments. Additionally, Japan's emphasis on precision medicine and the utilization of advanced genomic technologies are reshaping the biomarker landscape, contributing to better disease management and personalized healthcare solutions.

Features of the Global Biomarker Market

Market Size Estimates: Biomarker Market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Biomarker Market by various segments, such as by product, type, disease indication, application and region in terms of($B).

Regional Analysis: Biomarker Market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, types, disease indications, applications, and regions for the biomarker market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biomarker market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the biomarker market by product (consumables, services, and software), type (safety biomarkers, efficacy biomarkers, predictive biomarkers, surrogate biomarkers, pharmacodynamics biomarkers, prognostic biomarkers, and validation biomarkers), disease indication (cancer, infectious diseases, immune disorders, neurological disorders, cardiovascular disorders, and others), application (diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Biomarker Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Biomarker Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Biomarker Market by Product
  • 3.3.1: Consumables
  • 3.3.2: Services
  • 3.3.3: Software
• 3.4: Global Biomarker Market by Type
  • 3.4.1: Safety Biomarkers
  • 3.4.2: Efficacy Biomarkers
  • 3.4.3: Predictive Biomarkers
  • 3.4.4: Surrogate Biomarkers
  • 3.4.5: Pharmacodynamics Biomarkers
  • 3.4.6: Prognostic Biomarkers
  • 3.4.7: Validation Biomarkers
• 3.5: Global Biomarker Market by Disease Indication
  • 3.5.1: Cancer
  • 3.5.2: Infectious Diseases
  • 3.5.3: Immune Disorders
  • 3.5.4: Neurological Disorders
  • 3.5.5: Cardiovascular Disorders
  • 3.5.6: Others
• 3.6: Global Biomarker Market by Application
  • 3.6.1: Diagnostics
  • 3.6.2: Drug Discovery & Development
  • 3.6.3: Personalized Medicine
  • 3.6.4: Disease Risk Assessment
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Biomarker Market by Region
• 4.2: North American Biomarker Market
  • 4.2.1: North American Market by Product: Consumables, Services, and Software
  • 4.2.2: North American Market by Application: Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, and Others
• 4.3: European Biomarker Market
  • 4.3.1: European Market by Product: Consumables, Services, and Software
  • 4.3.2: European Market by Application: Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, and Others
• 4.4: APAC Biomarker Market
  • 4.4.1: APAC Market by Product: Consumables, Services, and Software
  • 4.4.2: APAC Market by Application: Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, and Others
• 4.5: ROW Biomarker Market
  • 4.5.1: ROW Market by Product: Consumables, Services, and Software
  • 4.5.2: ROW Market by Application: Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Biomarker Market by Product
  • 6.1.2: Growth Opportunities for the Global Biomarker Market by Type
  • 6.1.3: Growth Opportunities for the Global Biomarker Market by Disease Indication
  • 6.1.4: Growth Opportunities for the Global Biomarker Market by Application
  • 6.1.5: Growth Opportunities for the Global Biomarker Market by Region
• 6.2: Emerging Trends in the Global Biomarker Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Biomarker Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biomarker Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott Laboratories
• 7.2: QIAGEN
• 7.3: PerkinElmer
• 7.4: Merck
• 7.5: Bio-Rad Laboratories
• 7.6: Enzo Biochem
• 7.7: Charles River Laboratories
• 7.8: Siemens
• 7.9: Epistem
• 7.10: Eurofins Scientific